BOSTON, Feb. 26, 2026 — HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of oral, allosteric small molecules that target natural regulatory pockets, today announced it will present preclinical data from the Company’s interferon regulatory factor 5 (IRF5) program in a poster presentation at the 15th European Lupus Meeting taking place March 4-7, 2026, in Lisbon, Portugal.
Presentation Details
Title: Preclinical Evaluation of IRF5 Small Molecule Inhibitors with Potent Activity in Lupus-Relevant Systems.
Session: Poster Session 11: New Therapies, Including Biologics, Targeted Drugs, and Cell Therapies
About HotSpot Therapeutics, Inc.
HotSpot Therapeutics, Inc. is a biotechnology company that is pioneering a new class of allosteric drugs that target certain naturally occurring pockets on proteins called “natural hotspots.” These pockets are decisive in controlling a protein’s cellular function and have significant potential for new drug discovery by enabling the systematic design of potent and selective small molecules with novel pharmacology.
The Company’s proprietary Smart Allostery™ platform combines computational approaches and AI-driven data mining of large and diverse data sets to uncover hotspots, as well as tailored pharmacology toolkits and bespoke chemistry to drive the rapid discovery of novel hotspot-targeted small molecules. Leveraging this approach, HotSpot is building a broad pipeline of novel allosteric therapies for the treatment of autoimmune diseases.
